A. Van Den Abbeele

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)

George D. Demetri, Jayesh Desai, Jonathan A. Fletcher et al. · Journal of Clinical Oncology · 2004 · 103 citations

Diverse Genomic Mechanisms, Pathology, Tumor Biology +16

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy

David J. Sher, Peter Mauch, A. Van Den Abbeele et al. · Annals of Oncology · 2009 · 90 citations · Full text

Positron Emission Tomography, Lymphoid Neoplasia, Oncologic Imaging +10

Bond strengths of eight contemporary adhesives to enamel and to dentine: an <i>in vitro</i> study on bovine primary teeth

Ramin Atash, A. Van Den Abbeele · International Journal of Paediatric Dentistry · 2005 · 56 citations

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)

George D. Demetri, Jayesh Desai, Jonathan A. Fletcher et al. · Journal of Clinical Oncology · 2004 · 46 citations

Diverse Genomic Mechanisms, Pathology, Tumor Biology +16

Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM)

Palma Dileo, Rabinder Randhawa, Eric vanSonnenberg et al. · Journal of Clinical Oncology · 2004 · 32 citations

Surgical Oncology, Oncologic Imaging, Pet-mri +23